MAOB and Parkinson disease: Approved therapies for PD increase dopamine levels in the striatum via selective MAO-B inhibition—for example, rasagiline is prescribed as monotherapy in the early stages of PD and as add-on therapy to levodopa in advanced stages of PD [14].